The Lustgarten Foundation for Pancreatic Cancer Research Company Profile

13:14 EDT 31st October 2014 | BioPortfolio

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to date. The Foundation provides patient information and manages a national public awareness campaign. To learn more and to see Dr. Pausch's PSA, visit www.lustgarten.org.


News Articles [6969 Associated News Articles listed on BioPortfolio]

Salk professor named grantee in new pancreatic cancer research program

(Salk Institute) Ronald M. Evans, director of the Gene Expression Laboratory at Salk and Howard Hughes Medical Institute investigator, is one of three scientists chosen to receive $5 million in resear...

Factors that may contribute to pancreatic cancer: New insight

New research provides a better understanding of pancreatic cancer, and may help identify individuals at increased risk. Pancreatic cancer is a stealthy cancer that is usually detected at very late sta...

Pancreatic Cancer Will Be 2nd Deadliest Cancer by 2030: Study

MONDAY, May 19, 2014 -- Pancreatic cancer is set to become the second deadliest cancer in the United States by 2030, new research predicts. If the projections hold, pancreatic cancer will bypass breas...

Pancreatic Cancer to Become Second Most Fatal Cancer

Lung cancer is currently the deadliest cancer, followed by colorectal and breast cancers. But as deaths from many cancers drop, the Pancreatic Cancer Action Network predicts pancreatic cancer will ris...

Pancreatic cancer survival rates at standstill for four decades

Long-term survival from pancreatic cancer has failed to improve in 40 years – with the outlook remaining the lowest of the 21 most common cancers, according to new figures published by Cancer Resear...

Mayo Clinic researchers find that a molecule is linked to aggressive pancreatic cancer

One sub-form, Rac1b, played a role in pancreatic cancer. The Mayo team began their research by investigating why pancreatic cancer cells produce matrix metalloproteinases.

Cancer Research UK and Astellas join forces on pancreatic cancer treatment

Japanese drug major Astellas Pharma is joining forces with Cancer Research UK and its commercial arm, Cancer Research Technology (CRT), to find new drug targets in the fight against cancer, with an in...

Scientists discover new route to boost pancreatic cancer treatment

Cancer Research UK scientists have uncovered new insights into how a key pancreatic cancer drug – gemcitabine – is broken down in tumour cells, according to research* published in the British Jour...

PubMed Articles [8744 Associated PubMed Articles listed on BioPortfolio]

Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.

Pancreatic cancer is highly chemoresistant. A major contributing factor is the characteristic extensive stromal or fibrotic reaction, which comprises up to 90% of the tumor volume. Over the last decad...

Epigenetic targeting in pancreatic cancer.

The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years...

Association between Allergies and Risk of Pancreatic Cancer.

Less than 10% of pancreatic cancer cases survive 5 years, yet its etiology is not well understood. Studies suggest allergies are associated with reduced pancreatic cancer risk. Our study collected add...

Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.

Wnt signaling pathway plays an important role in physiological and pathological process, including in the occurrence and development of tumor. The purpose of this study is to determine whether Wnt2 an...

Oxidative stress and cytokines in the pathogenesis of pancreatic cancer.

Pancreatic cancer is one of the most aggressive, drug-resistant and lethal types of cancer with poor prognosis. Various factors including reactive oxygen species, cytokines, growth factors, and extrac...

Clinical Trials [3629 Associated Clinical Trials listed on BioPortfolio]

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcita...

Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic cancer. ...

BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study

The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and abraxane. E...

Local Invasion of Pancreatic Cancer

Pancreatic cancer often spreads through local invasion into local structures, including fat, blood vessels, nerves, and nearby organs (stomach, duodenum, spleen, bile duct). Local microsco...

Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer

Pancreatic cancer has traditionally been treated with chemotherapy and radiation therapy with limited results. Preliminary studies of parts of this program in patients with advanced panc...

Companies [2332 Associated Companies listed on BioPortfolio]

The Lustgarten Foundation for Pancreatic Cancer Research

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit support...

The Lustgarten Foundation

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research. Founded in 1998, the Foundation provides critica...

Sky Foundation, Inc.

After being diagnosed with pancreatic cancer in 2007 and responding well to treatment, Kasselman established Sky Foundation to fund research for the Sky Foundation Pancreatic Cancer Research Fund at t...

Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the only national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organizat...

Pancreatic Cancer Action

About Pancreatic Cancer Action: 5 year survival rates for pancreatic cancer have not changed in over 40 years and it is our mission to change this by way of increased awareness of pancreatic cancer...

More Information about "The Lustgarten Foundation for Pancreatic Cancer Research" on BioPortfolio

We have published hundreds of The Lustgarten Foundation for Pancreatic Cancer Research news stories on BioPortfolio along with dozens of The Lustgarten Foundation for Pancreatic Cancer Research Clinical Trials and PubMed Articles about The Lustgarten Foundation for Pancreatic Cancer Research for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Lustgarten Foundation for Pancreatic Cancer Research Companies in our database. You can also find out about relevant The Lustgarten Foundation for Pancreatic Cancer Research Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record